You are here

  • Home
  • Online First
  • EGFR signalling and oncogenic pathway signature in colorectal cancer

Article Text

Article menu

other Versions

Download PDFPDF
PostScript
Letter
EGFR signalling and oncogenic pathway signature in colorectal cancer
  1. Ibrahim Halil Sahin1,
  2. Ahmet Afsin Oktay2
  1. 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2Department of Internal Medicine, Saint Francis Hospital, Evanston, Illinois, USA
  1. Correspondence to Dr Ibrahim Halil Sahin, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; ihsahin{at}mdanderson.org

https://doi.org/10.1136/gutjnl-2013-304781

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sun et al1 reported a novel stratification model for classifying patients with colorectal cancer by characterising the gene expression profile of the tumours with wild type and mutant KRAS, BRAF and PIK3CA. The authors claimed that the combined transcription signature of these mutant signal molecules might help clinicians identify patients, whose tumour could have similar transcription signature without any mutation and who …

    View Full Text

    Footnotes

    • Contributors IHS and AAO were involved in the discussion and manuscript writing process.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.